An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

The present invention is to inhibit the cracks of the protective layer when producing the three-layered capsules and to solve the problems of cracks when producing and storing in the cooled condition to provide a three-layered capsule and a production thereof without suck generation of cracks.

The present invention provides a three-layered capsule which comprises: a content comprising a main agent dispersed or solubilized in oil material, a protective layer, formed on the content, comprising edible refined and processed oil, and a shell, formed on an outside the protective layer, comprising natural polymer, the three layers being present concentrically, and a producing method of the capsule.

The present invention is to inhibit the cracks of the protective layer when producing the three-layered capsules and to solve the problems of cracks when producing and storing in the cooled condition to provide a three-layered capsule and a production thereof without suck generation of cracks.

The present invention provides a three-layered capsule which comprises: a content comprising a main agent dispersed or solubilized in oil material, a protective layer, formed on the content, comprising edible refined and processed oil, and a shell, formed on an outside the protective layer, comprising natural polymer, the three layers being present concentrically, and a producing method of the capsule.

A composition for manufacturing a water-soluble powder via spray-drying. The composition has an emulsion and a core material dispersed therein. The emulsion has at least one carbohydrate membrane-forming material and a sugar alcohol mixed with a solvent. The core material at least has one or more active ingredients. After spray-drying, the water-soluble powder comprises the core material encapsulated by a membrane formed by the at least one carbohydrate membrane-forming material and the sugar alcohol.

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.

The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 mol glycodeoxycholic acid (GDCA)/gram/hour and >2 mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 mol GDCA/g/hr and >7 mol TDCA/g/hr when measured over 30 minutes.

The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 mol glycodeoxycholic acid (GDCA)/gram/hour and >2 mol taurodeoxycholic acid (TDCA)/gram/hour when measured over 1 hour and 5 hours, respectively, or degrades >65 mol GDCA/g/hr and >7 mol TDCA/g/hr when measured over 30 minutes.

The invention is directed to a nanoprecipitate comprising a cannabinoid or a terpene, or combination thereof, a process of preparing the nanoprecipitate, and oral formulations comprising the nanoprecipitate, including beverage additives and edibles.